Where the Litigation Goes from Here in Light of New Investigations by the Senate and the FDA

Recording Date: April 21, 2010
Duration: 88 minutes
Self Study/Alternate Format CLE: Self-study credit may be available in AZ, CA, CO, FL, GA, ID, LA, ME, NV, NH, TX, UT, VT, WA, WV and WY for watching a video or listening to an audio recording. Refer to your state bar’s MCLE guidelines for the number of reportable credits permissible via these formats.

Didn’t Attend?

Purchase the Audio Package for $149!

Purchase the teleconference Audio Package (includes MP3 audio recording files and handbook on CD). To order or learn more, click here, call 484-324-2755, or email allison.emery@litigationconferences.com.

Attendees get the teleconference Audio Package for 50% off!

Agenda and Speakers

Where the Litigation Goes from Here in Light of New Investigations by the Senate and the FDA
• Science update
• The recent New York Times article, what the Senate investigation found, the FDA’s position or conflicting positions on the drug, and what GlaxoSmithKline PLC knew and when it knew it
• How these findings will impact the pending federal and state cases set for trial this summer
• The statute of limitation issues–in general and for post-black box cases, in light of the recent news
• Determining whether and when to take on an Avandia case
• The anticipated defense response to these findings
• When to expect a new FDA advisory committee and their findings

Speakers:
Vance Andrus, Esq., Andrus-Boudreaux, P.L.C., Denver
Bryan Aylstock, Esq., Aylstock Witkin Kreis & Overholtz, P.L.C., Pensacola, FL
Neil Overholtz, Esq., Aylstock Witkin Kreis & Overholtz, P.L.C., Pensacola, FL
Aimee Wagstaff, Esq., Andrus-Boudreaux, P.L.C., Denver